Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pentaxim

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pentavac

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15–18 Months of Age in Mexico: A Randomized…
Background: The live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in a number of dengue endemic countries for… Expand
2017
2017
The status of vaccine availability and associated factors in Tshwane government clinics.
BACKGROUND Vaccines have greatly contributed to the control of vaccine-preventable diseases and to human development. Efforts by… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
2012
2012
Immunogenicity and safety of a DTaP-IPV//PRP∼T vaccine (Pentaxim) booster dose during the second year of life in Indian children primed with the same vaccine
ObjectiveTo evaluate the immunogenicity and safety of a pentavalent (diphtheria, tetanus, acellular pertussis, inactivated… Expand
  • table I
  • table II
  • table III
2011
2011
Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of…
OBJECTIVE To assess the immunogenicity and safety data for a pentavalent combination vaccine containing acellular pertussis… Expand
  • figure 1
  • table II
  • table I
  • figure 2
  • table III
2011
2011
Immunogenicity and Safety of an Investigational Hexavalent Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus-hepatitis B-Haemophilus influenzae B Conjugate Combined Vaccine in Healthy 2…
Background and Aims: Assessment of a new, fully liquid, investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi… Expand
2011
2011
Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for…
  • Rong Cheng Li, Feng Xiang Li, +16 authors E. Ortiz
  • Vaccine
  • 2011
    • Corpus ID: 205584758
The aim was to demonstrate the immunogenicity and safety of a DTaP-IPV//PRP-T combined vaccine (Pentaxim(®)) compared to… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2011
2011
Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary…
This study assessed the antibody persistence, and the immunogenicity and safety of a booster dose of a DTaP-IPV//PRP∼T (Pentaxim… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 3
2010
2010
Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6…
The objective of this study was to evaluate the immunogenicity and safety of a pentavalent vaccine (Pentaxim) containing… Expand
2009
2009
Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
This study assessed the booster immune response to a pentavalent combination vaccine containing diphtheria, tetanus, acellular… Expand
2008
2008
Primary Vaccination of Indian Infants at 6, 10, 14 Weeks of Age with a Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus Influenzae Type B Conjugate Vaccine (Pentaxim)
Background: Data on the immunogenicity and safety of acellular pertussis-based combination vaccines when given in the WHO… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE